71 related articles for article (PubMed ID: 9832306)
1. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
Barbouche R; Fenouillet E; Papandréou MJ; Kiény MP; Sabatier JM
J Pept Res; 1998 Oct; 52(4):283-8. PubMed ID: 9832306
[TBL] [Abstract][Full Text] [Related]
2. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
3. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
[TBL] [Abstract][Full Text] [Related]
4. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
Barbouche R; Miquelis R; Sabatier JM; Fenouillet E
J Pept Sci; 1998 Dec; 4(8):479-85. PubMed ID: 9927254
[TBL] [Abstract][Full Text] [Related]
5. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
[TBL] [Abstract][Full Text] [Related]
6. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
[TBL] [Abstract][Full Text] [Related]
7. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
8. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
Carlier E; Mabrouk K; Moulard M; Fajloun Z; Rochat H; De Waard M; Sabatier JM
J Pept Res; 2000 Dec; 56(6):427-37. PubMed ID: 11152302
[TBL] [Abstract][Full Text] [Related]
9. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
10. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
11. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
[TBL] [Abstract][Full Text] [Related]
12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
13. Recombinant HIV envelope expressed in an alpha-glucosidase I-deficient CHO cell line and its parental cell line in the presence of 1-deoxynojirimycin is functional.
Fenouillet E; Papandréou MJ; Jones IM
Virology; 1997 Apr; 231(1):89-95. PubMed ID: 9143306
[TBL] [Abstract][Full Text] [Related]
14. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
[TBL] [Abstract][Full Text] [Related]
15. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E
Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580
[TBL] [Abstract][Full Text] [Related]
16. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
17. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
18. SPC3, a nontoxic peptide inhibitor of HIV infection.
Sabatier JM; Baghdiguian S; Yahi N; Rochat H; Van Rietschoten J; Fantini J
In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):415-8. PubMed ID: 8589880
[No Abstract] [Full Text] [Related]
19. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
[TBL] [Abstract][Full Text] [Related]
20. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
